Semaglutide has proven to be a life-changing medication for many people
The Study at a Glance Who was studied: 132 children and adolescents aged 1017 with type 2 diabetes Duration: 52 weeks (with the primary endpoint measured at week 26) Design: Randomized, double-blind, placebo-controlled Drug: Oral semaglutide at once-daily doses of 3 mg, 7 mg, or 14 mg Background therapy: Participants continued on metformin, basal insulin, or both The Results The trial met its primary endpoint
Once the patient has reached the maintanence dose, follow up appointments can be scheduled according to the needs of the patient and the physicians discretion
Your once-weekly routine with Ozempic pen TEXT ON-SCREEN: Su rutina con OZEMPIC semaglutide injection 0.5, 1 y 2 mg Consulte la Informacin de prescripcin, la Gua del medicamento y las Indicaciones de uso en el enlace dado
10.1016/j.humpath.2007.11.015 13 GallwitzB.GiorginoF